Big Pharma Pushes Watson's Oxytrol To Specialty Area
This article was originally published in The Pink Sheet Daily
Executive Summary
Continued decline in sales of the overactive bladder patch reinforces Watson focus on the urologist specialty area; firm cites inadequate resources to compete with big pharma in the primary care market.